"10.1371_journal.pone.0096187","plos one","2014-05-13T00:00:00Z","David A Wohl; Laveeza Bhatti; Catherine B Small; Howard Edelstein; Henry H Zhao; David A Margolis; Edwin DeJesus; Winkler G Weinberg; Lisa L Ross; Mark S Shaefer","AIDS Clinical Trials Unit, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America; AIDS Healthcare Foundation, Beverly Hills, California, United States of America; New York Medical College, Valhalla, New York, United States of America; Alameda County Medical Center, Oakland, California, United States of America; GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America; Orlando Immunology Center, Orlando, Florida, United States of America; Kaiser Foundation Health Plan of Georgia, Inc, Atlanta, Georgia, United States of America; ViiV Healthcare, Research Triangle Park, North Carolina, United States of America","Analyzed the data: HHZ DAW LLR DAM MSS. Wrote the paper: DAW DAM, HHZ LLR MSS LB CBS HE ED WGW. Contributed substantially to acquisition of patient clinical study data: DAW LB CBS HE ED WGW. Conceived and designed the study:  DAW DAM HHZ LLR MSS LB CBS HE ED WGW.","The EPZ113734 study was sponsored by ViiV Healthcare (www.viivhealthcare.com) which along with Dr. Wohl developed the study design with input from study investigators who were contracted by ViiV Healthcare to collect and assist in the analyses of the clinical data, and contracted with GlaxoSmithKline to collect and analyze the clinical data. H.H.Z. and D.A.M. are employed by GlaxoSmithKline. L.L.R. and M.S.S. are employed by ViiV Healthcare (the makers of the fixed dose formulation of abacavir and lamivudine). All four have retirement benefits that include GlaxoSmithKline stock or options. D.W. and C.B.S. previously had grants from ViiV Healthcare. E.D. has received payment for lectures (including Speakers Bureaus) from Gilead Sciences and Janssen as has L.B. from BristolMyersSquibb, Janssen, Merck and ViiV. L.B. holds stock in Gilead Sciences and has served on advisory boards for Boehringer Ingelheim, BristolMyersSquibb, Genentech, and Gilead Sciences. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2014","05","David A Wohl","DAW",10,TRUE,11,NA,5,10,TRUE,TRUE,FALSE,0,NA,FALSE
